Slide 1: Insulet Corporation Q2 2023 Earnings
Insulet Corporation Q2 2023 Earnings August 8, 2023 Christian D Podder Since 2020
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward- looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward- looking statem
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant curr
Slide 4: Recent Highlights
Recent Highlights Highlights • Commercially launched Omnipod 5 in the United Kingdom • Submitted the Omnipod 5 iOS App for the iPhone to the FDA for 510(k) clearance • Achieved record U.S. and Total Omnipod new customer starts • Presented additional real-world evidence for Omnipod 5 at the American
Slide 5: Strategic Highlights
Strategic Highlights Grant H Morgan M Alecia B Podder Since 2022 Podder Since 2009 Podder Since 2017 Expand Access & Awareness International Innovation & Clinical • Record quarterly U.S. and Total Omnipod new • Building cloud-based infrastructure to deliver the • Submitted Omnipod 5 iOS App for the
Slide 6: Financial Performance
Financial Performance Total Revenue & Growth Rates1 U.S. Omnipod Revenue and Growth Rates 1 Adjusted Gross Profit and Margin2 Int'l Omnipod Revenue and Growth Rates1 Adjusted Operating Income & Margin2 Total Omnipod Revenue & Growth Rates1 $4M 1. Growth rates are on a year-over-year basis and for 20
Slide 7: Key Commercial Metrics- Q2 2023
Key Commercial Metrics- Q2 2023 ~75% ~20% >90% U.S. New Customer Starts By Product of U.S. New of U.S. New of U.S. Volume Starts were MDI Starts were through Type 2 Pharmacy ~10% Stable Global Global Attrition Utilization Note: All commercial metrics are directional estimates derived from various in
Slide 8: Product Development Status- Q2 2023
Product Development Status- Q2 2023 Legend Innovation Pipeline U.S. Commercialized Regulatory Product International Submission Development Classic Omnipod Omnipod DASH Omnipod 5 U.S. full market release August 2022 CE Mark September 2022; w/ G6 UK full market release June 2023 On track for additiona
Slide 9: Guidance Highlights - 2023
Guidance Highlights - 2023 FY 2023 Q3 2023 FY 2023 Adjusted FY 2023 Adjusted Revenue Growth1 Revenue Growth1 Gross Margin2 Operating Margin2 High-Single 22% to 25% 18% to 21% 65% to 66% Digits (closer to the high end) U.S. Omnipod U.S. Omnipod 33% to 36% 27% to 30% International Omnipod Internationa
Slide 10: Revenue Guidance Reconciliation
Revenue Guidance Reconciliation FY 2023 Q3 2023 Revenue Growth Currency Revenue Growth Currency GAAP Impact Constant Currency GAAP Impact Constant Currency U.S. Omnipod 33% to 36% —% 33% to 36% 27% to 30% —% 27% to 30% International Omnipod 10% to 13% 3% 7% to 10% 10% to 13% 8% 2% to 5% Total Omnipo
Slide 11: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures % of % of % of % of % of FY2020 Revenue FY2021 Revenue FY2022 Revenue Q2 2022 Revenue Q2 2023 Revenue Total Revenue GAAP Growth Rate 22.5% 21.5% 18.8% 13.8% 32.4% Less: Currency Impact 0.6% 1.8% (3.7) % (3.9) % 0.2% Constant Currency 21.9% 19.7% 22.5% 17.7% 32.2%